Monday, March 30, 2015

Gene Variant Predicts Antidepressant Response and Side Effect Severity


A variant in a gene called ABCB1 can predict how a person will respond to certain antidepressants, reports a new study in AJP in Advance titled “ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial.”

The study involved 683 patients who received escitalopram, sertraline, or extended-release venlafaxine; the participants also had their ABCB1 gene sequenced. All three of these medications interact with P-glycoprotein, the protein encoded by the ABCB1 gene that functions in transporting antidepressants across the blood-brain barrier.

The authors found a variant called rs10245483 had a significant effect on remission rate and side effects, though it varied depending on the medication. People who had two copies of the common variant (G/G) responded better and had fewer side effects with escitalopram and sertraline. In contrast, people with the minor variant (T/T) responded better and had fewer side effects with venlafaxine.

The degree of remission correlated with the relative cognition of the patient. G/G participants had a greater rate of remission with escitalopram if their cognition was intact, whereas people with T/T displayed a greater rate of remission with venlafaxine if their cognition was impaired.

To read about a potential pharmacogenetic biomarker that may help inform sobriety treatment, see the Psychiatric News article “Genetic Analysis Identifies Possible Acamprosate Biomarker.”

(shutterstock/appler)

Disclaimer

The content of Psychiatric News does not necessarily reflect the views of APA or the editors. Unless so stated, neither Psychiatric News nor APA guarantees, warrants, or endorses information or advertising in this newspaper. Clinical opinions are not peer reviewed and thus should be independently verified.